THX Pharma和Biocodex伙伴为选择有限的稀有基因疾病制定治疗方法。 THX Pharma and Biocodex partner to develop treatments for rare genetic disorders with limited options.

THX Pharma和Biocodex宣布了一项战略许可证协议,以发展和商业化治疗三种罕见遗传疾病:Batten疾病、Gaucher疾病和Niemann-Pick C型。 伙伴关系旨在推进这些条件的治疗,目前这些条件的治疗选择有限。 THX Pharma and Biocodex have announced a strategic licensing agreement to develop and commercialize treatments for three rare genetic disorders: Batten disease, Gaucher disease, and Niemann-Pick type C. The partnership aims to advance therapies for these conditions, which currently have limited treatment options. 该协议扩大了两家公司在罕见疾病研究与开发方面的投资组合,为病人和保健提供者带来潜在好处。 The agreement expands both companies’ portfolios in rare disease research and development, with potential benefits for patients and healthcare providers.